• Explore /
  • Poster
  • / NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

Abstract Poster

Authors

null

Louis Fehrenbacher

National Surgical Adjuvant Breast and Bowel Project and Kaiser Permanente Northern California, Vallejo, CA

Louis Fehrenbacher , Jong-Hyeon Jeong , Priya Rastogi , Charles E. Geyer Jr., Soonmyung Paik , Patricia A. Ganz , Stephanie R. Land , Joseph P. Costantino , Sandra M. Swain , Eleftherios P. Mamounas , Norman Wolmark

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Cytotoxic Chemotherapy

Clinical Trial Registration Number

NCT01275677

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS1139)

DOI

10.1200/jco.2013.31.15_suppl.tps1139

Abstract #

TPS1139

Poster Bd #

33F

Abstract Disclosures

Similar Posters

First Author: Louis Fehrenbacher

First Author: Rosana Gnanajothy

First Author: Katherine Lovat

First Author: M. Luque